News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
260,398 Results
Type
Article (13891)
Company Profile (295)
Press Release (246212)
Section
Business (79349)
Career Advice (154)
Deals (13182)
Drug Delivery (32)
Drug Development (50289)
Employer Resources (31)
FDA (5671)
Job Trends (5117)
News (144099)
Policy (10016)
Tag
Academia (901)
Alliances (21476)
Alzheimer's disease (736)
Approvals (5646)
Artificial intelligence (63)
Bankruptcy (97)
Best Places to Work (4498)
Biotechnology (242)
Breast cancer (66)
Cancer (699)
Cardiovascular disease (62)
Career advice (135)
CAR-T (57)
Cell therapy (178)
Clinical research (39818)
Collaboration (239)
Compensation (99)
COVID-19 (1002)
C-suite (68)
Cystic fibrosis (66)
Data (798)
Diabetes (73)
Diagnostics (1201)
Earnings (28986)
Events (46859)
Executive appointments (193)
FDA (5965)
Funding (252)
Gene editing (55)
Gene therapy (148)
GLP-1 (301)
Government (1063)
Healthcare (6533)
Infectious disease (1037)
Inflammatory bowel disease (94)
IPO (7183)
Job creations (863)
Job search strategy (130)
Layoffs (184)
Legal (1374)
Lung cancer (111)
Manufacturing (74)
Medical device (2552)
Medtech (2553)
Mergers & acquisitions (6103)
Metabolic disorders (225)
Neuroscience (946)
NextGen Class of 2024 (1998)
Non-profit (844)
Northern California (951)
Obesity (124)
Opinion (91)
Parkinson's disease (61)
Patents (52)
People (24994)
Pharmaceutical (50)
Phase I (14012)
Phase II (18522)
Phase III (11736)
Pipeline (324)
Postmarket research (846)
Preclinical (5930)
Radiopharmaceuticals (205)
Rare diseases (169)
Real estate (1409)
Regulatory (8207)
Research institute (930)
Southern California (868)
Startups (1964)
United States (7656)
Vaccines (160)
Weight loss (76)
Date
Today (24)
Last 7 days (419)
Last 30 days (2198)
Last 365 days (20738)
2024 (19058)
2023 (22413)
2022 (26822)
2021 (27810)
2020 (23357)
2019 (16224)
2018 (11738)
2017 (13745)
2016 (11845)
2015 (14360)
2014 (10393)
2013 (7489)
2012 (7533)
2011 (7617)
2010 (7433)
Location
Africa (146)
Asia (16833)
Australia (2839)
California (2158)
Canada (718)
China (166)
Colorado (82)
Connecticut (86)
Europe (36255)
Florida (232)
Georgia (62)
Illinois (128)
Indiana (54)
Kansas (55)
Maryland (300)
Massachusetts (1712)
Michigan (48)
Minnesota (94)
New Jersey (549)
New York (615)
North Carolina (399)
Northern California (951)
Ohio (79)
Pennsylvania (429)
South America (207)
Southern California (868)
Texas (232)
Washington State (221)
260,398 Results for "sangamo therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Regulatory
Sangamo’s Fabry Gene Therapy Could Hit Market 3 Years Earlier With FDA Accelerated Approval Pathway
The regulator agreed to allow Sangamo Therapeutics to use data to seek accelerated approval for its Fabry gene therapy candidate, eliminating the need for an additional registrational study and potentially shortening the time-to-market by three years.
October 23, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast
November 4, 2024
·
1 min read
Drug Development
Despite Late-Stage Hemophilia Win, Sangamo Remains in Do-or-Die Situation
Sangamo and Pfizer’s hemophilia A gene therapy candidate scored a Phase III victory last week. However, with the genomic medicine company soon to run out of cash, Sangamo’s short-term prospects look bleak but not unsalvageable, analysts say.
July 31, 2024
·
3 min read
·
Tyler Patchen
Press Releases
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results
November 12, 2024
·
19 min read
Business
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
Sangamo Therapeutics, Inc., a genomic medicines company, reported business highlights and first quarter 2024 financial results.
May 9, 2024
·
17 min read
Deals
Cash-Strapped Sangamo Gets Lifeline from Genentech in Potential $1.9B Neuro Deal
Sangamo Therapeutics announced Tuesday it secured an exclusive licensing agreement with Roche’s Genentech, which is paying $50 million in near-term upfront fees and milestone payments to develop novel genomic medicines for neurodegenerative diseases.
August 6, 2024
·
2 min read
·
Tyler Patchen
Business
Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its first quarter 2024 financial results after the market closes on Thursday, May 9, 2024.
May 2, 2024
·
1 min read
Drug Development
Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing
Sangamo Therapeutics, Inc. today presented pre-clinical data showcasing its novel next-generation integrase technology engineered to enable large-scale genome editing.
May 9, 2024
·
4 min read
Press Releases
Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain
November 19, 2024
·
6 min read
Deals
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
Sangamo Therapeutics, Inc. today announced that it has entered into a securities purchase agreement with institutional investors, providing for the purchase and sale of an aggregate of 24,761,905 shares of its common stock.
March 22, 2024
·
4 min read
1 of 26,040
Next
